1. Home
  2. NTRB vs LSTA Comparison

NTRB vs LSTA Comparison

Compare NTRB & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutriband Inc.

NTRB

Nutriband Inc.

HOLD

Current Price

$3.06

Market Cap

35.3M

Sector

Health Care

ML Signal

HOLD

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$3.36

Market Cap

28.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRB
LSTA
Founded
2016
1980
Country
United States
United States
Employees
3
N/A
Industry
Industrial Specialties
Misc Health and Biotechnology Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.3M
28.9M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
NTRB
LSTA
Price
$3.06
$3.36
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
9.7K
95.2K
Earning Date
05-29-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.42
EPS
N/A
N/A
Revenue
N/A
$35,283,868.00
Revenue This Year
$30.17
N/A
Revenue Next Year
$3,394.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
56.90
52 Week Low
$2.90
$1.81
52 Week High
$11.68
$5.07

Technical Indicators

Market Signals
Indicator
NTRB
LSTA
Relative Strength Index (RSI) 36.53 45.00
Support Level $2.90 $3.06
Resistance Level $3.67 $3.41
Average True Range (ATR) 0.19 0.13
MACD -0.03 -0.01
Stochastic Oscillator 14.58 2.86

Price Performance

Historical Comparison
NTRB
LSTA

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: